

Alexander M Menzies

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/87941/publications.pdf>

Version: 2024-02-01

207
papers

18,664
citations

16451
64
h-index

13771
129
g-index

209
all docs

209
docs citations

209
times ranked

20188
citing authors

#	ARTICLE	IF	CITATIONS
1	FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. <i>Annals of Oncology</i> , 2022, 33, 99-106.	1.2	15
2	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. <i>European Journal of Cancer</i> , 2022, 162, 22-33.	2.8	28
3	Multimic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. <i>Cancer Cell</i> , 2022, 40, 88-102.e7.	16.8	64
4	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. <i>Pathology</i> , 2022, 54, 6-19.	0.6	3
5	Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1843-e1849.	3.6	22
6	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APLUS. <i>European Journal of Cancer</i> , 2022, 163, 79-87.	2.8	17
7	Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1068-1080.	1.6	43
8	Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. <i>Australasian Journal of Dermatology</i> , 2022, 63, .	0.7	1
9	Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. <i>Pathology</i> , 2022, , .	0.6	1
10	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.5	21
11	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Frontiers in Oncology</i> , 2022, 12, 820510.	2.8	2
12	Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, .	1.2	0
13	Immune Related Adverse Events of the Thyroid - A Narrative Review. <i>Frontiers in Endocrinology</i> , 2022, 13, .	3.5	19
14	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. , 2022, 10, e004771.		16
15	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
16	Immunotherapy-related acute kidney injury: Kidney biopsy or not?. <i>Nephrology</i> , 2021, 26, 89-90.	1.6	1
17	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	6.4	27
18	Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. <i>European Journal of Cancer</i> , 2021, 142, 10-17.	2.8	16

#	ARTICLE	IF	CITATIONS
19	Applying adjuvant therapy for melanoma into clinical practice. Expert Review of Anticancer Therapy, 2021, 21, 129-133.	2.4	1
20	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
21	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine, 2021, 27, 301-309.	30.7	218
22	Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners. Patient, 2021, 14, 635-647.	2.7	8
23	Recent advancements in melanoma management. Internal Medicine Journal, 2021, 51, 327-333.	0.8	4
24	Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3704-e3713.	3.6	98
25	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 2021, 148, 61-75.	2.8	15
26	PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. Frontiers in Immunology, 2021, 12, 672521.	4.8	13
27	Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location. Strahlentherapie Und Onkologie, 2021, 197, 1104-1112.	2.0	5
28	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2021, 22, 836-847.	10.7	104
29	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/â~ Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. Cancers, 2021, 13, 3186.	3.7	11
30	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Annals of Oncology, 2021, 32, 766-777.	1.2	22
31	Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Annals of Oncology, 2021, 32, 917-925.	1.2	76
32	Novel adjuvant options for cutaneous melanoma. Annals of Oncology, 2021, 32, 854-865.	1.2	31
33	Immunotherapy use outside clinical trial populations: never say never?. Annals of Oncology, 2021, 32, 866-880.	1.2	22
34	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	2.8	12
35	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. Clinical Cancer Research, 2021, 27, 5280-5288.	7.0	21
36	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 2021, 153, 168-178.	2.8	14

#	ARTICLE	IF	CITATIONS
37	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e343-e344.	10.7	2
38	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. <i>European Journal of Cancer</i> , 2021, 153, 8-15.	2.8	1
39	Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. <i>European Journal of Cancer</i> , 2021, 153, 234-241.	2.8	15
40	Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2021, 153, 213-222.	2.8	7
41	Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews. <i>BMC Cancer</i> , 2021, 21, 1014.	2.6	3
42	Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. <i>European Journal of Cancer</i> , 2021, 157, 214-224.	2.8	62
43	A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. <i>Oncolimmunology</i> , 2021, 10, 1875639.	4.6	30
44	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		34
45	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. <i>Frontiers in Endocrinology</i> , 2021, 12, 764138.	3.5	22
46	PET imaging for cancer immunotherapy: the Immuno-PET. <i>Annals of Oncology</i> , 2021, , .	1.2	1
47	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. <i>Oncolimmunology</i> , 2020, 9, 1659093.	4.6	62
48	Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. <i>Cancer</i> , 2020, 126, 86-97.	4.1	113
49	Preferences for Immunotherapy in Melanoma: A Systematic Review. <i>Annals of Surgical Oncology</i> , 2020, 27, 571-584.	1.5	36
50	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 358-365.	3.3	51
51	The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. <i>Oncologist</i> , 2020, 25, e602-e605.	3.7	35
52	Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 5926-5933.	7.0	41
53	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Cancers</i> , 2020, 12, 2228.	3.7	22
54	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. <i>Cancer Immunology Research</i> , 2020, 8, 1346-1353.	3.4	13

#	ARTICLE	IF	CITATIONS
55	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. , 2020, 8, e001488.		22
56	The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients â€” A Potential Paradigm Shift in Management. Annals of Surgical Oncology, 2020, 27, 2188-2200.	1.5	4
57	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. , 2020, 8, e000604.		98
58	Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. Frontiers in Oncology, 2020, 10, 757.	2.8	11
59	Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases. Pathology, 2020, 52, 515-521.	0.6	5
60	Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. Frontiers in Immunology, 2020, 11, 372.	4.8	20
61	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clinical Cancer Research, 2020, 26, 5086-5091.	7.0	27
62	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	1.6	23
63	Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid, 2020, 30, 1458-1469.	4.5	44
64	Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2020, 26, 4064-4071.	7.0	50
65	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nature Communications, 2020, 11, 1897.	12.8	165
66	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Annals of Oncology, 2020, 31, 724-744.	1.2	129
67	First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.. Journal of Clinical Oncology, 2020, 38, 10002-10002.	1.6	57
68	Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.. Journal of Clinical Oncology, 2020, 38, 10005-10005.	1.6	26
69	The nature and management of acquired resistance to PD1-based therapy in melanoma.. Journal of Clinical Oncology, 2020, 38, 10014-10014.	1.6	4
70	Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.. Journal of Clinical Oncology, 2020, 38, 10015-10015.	1.6	18
71	Activity and safety of third-line BRAF-targeted therapy (TT) following first-line TT and second-line immunotherapy (IT) in advanced melanoma.. Journal of Clinical Oncology, 2020, 38, 10049-10049.	1.6	3
72	Circulating tumor DNA (ctDNA) using Guardant360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2020, 38, 10050-10050.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.. Journal of Clinical Oncology, 2020, 38, TPS10087-TPS10087.	1.6	9
74	Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. Oncotarget, 2020, 11, 4016-4027.	1.8	6
75	Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only, compared to therapeutic lymph node dissection: First results of the PRADO trial.. Journal of Clinical Oncology, 2020, 38, 10064-10064.	1.6	0
76	Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).. Journal of Clinical Oncology, 2020, 38, 10026-10026.	1.6	2
77	A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.. Journal of Clinical Oncology, 2020, 38, TPS10088-TPS10088.	1.6	2
78	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nature Medicine, 2019, 25, 1243-1250.	30.7	133
79	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155
80	Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5499-5506.	3.6	85
81	Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. Journal of Clinical Oncology, 2019, 37, 3142-3151.	1.6	83
82	Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. Cancer Chemotherapy and Pharmacology, 2019, 83, 693-704.	2.3	21
83	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 948-960.	10.7	346
84	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncology, The, 2019, 20, 961-971.	10.7	126
85	Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Annals of Oncology, 2019, 30, 815-822.	1.2	77
86	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology, 2019, 30, 1154-1161.	1.2	170
87	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIb/IV CheckMate 511 Trial. Journal of Clinical Oncology, 2019, 37, 867-875.	1.6	258
88	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell and Melanoma Research, 2019, 32, 553-563.	3.3	28
89	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, 2019, 35, 238-255.e6.	16.8	547
90	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. Cancers, 2019, 11, 1905.	3.7	14

#	ARTICLE	IF	CITATIONS
91	Hypermethylation of Circulating Free DNA in Cutaneous Melanoma. Applied Sciences (Switzerland), 2019, 9, 5074.	2.5	6
92	Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. International Journal of Cancer, 2019, 144, 1049-1060.	5.1	54
93	Inter- and inpatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. Histopathology, 2019, 74, 817-828.	2.9	16
94	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. Clinical Cancer Research, 2019, 25, 1557-1563.	7.0	249
95	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. Clinical Cancer Research, 2019, 25, 1272-1279.	7.0	57
96	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. OncoImmunology, 2019, 8, e1537581.	4.6	61
97	Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. Cancer, 2019, 125, 884-891.	4.1	43
98	A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy.. Journal of Clinical Oncology, 2019, 37, 9502-9502.	1.6	6
99	Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. Journal of Clinical Oncology, 2019, 37, 9503-9503.	1.6	34
100	Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.. Journal of Clinical Oncology, 2019, 37, 9511-9511.	1.6	3
101	Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma.. Journal of Clinical Oncology, 2019, 37, 9583-9583.	1.6	2
102	A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).. Journal of Clinical Oncology, 2019, 37, TPS9600-TPS9600.	1.6	16
103	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. Journal of Clinical Oncology, 2019, 37, TPS9605-TPS9605.	1.6	16
104	Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets).. Journal of Clinical Oncology, 2019, 37, 9581-9581.	1.6	2
105	Clinical features and response to immune checkpoint inhibitors (ICIs) in pregnancy-associated melanoma (PAM).. Journal of Clinical Oncology, 2019, 37, 9564-9564.	1.6	0
106	Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).. Journal of Clinical Oncology, 2019, 37, 9542-9542.	1.6	2
107	Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary, 2018, 21, 274-282.	2.9	25
108	Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. Pigment Cell and Melanoma Research, 2018, 31, 404-410.	3.3	34

#	ARTICLE	IF	CITATIONS
109	Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-“Programmed Cell Death 1 Antibodies. <i>JAMA Oncology</i> , 2018, 4, 717.	7.1	229
110	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology</i> , The, 2018, 19, 310-322.	10.7	486
111	Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. <i>European Journal of Cancer</i> , 2018, 91, 116-124.	2.8	69
112	Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 509-515.	3.3	34
113	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-“PD-1 Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 3036-3045.	7.0	297
114	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 672-681.	10.7	732
115	Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 250-255.	1.2	304
116	Leptomeningeal melanoma-“A case series in the era of modern systemic therapy. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 120-124.	3.3	29
117	The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. <i>European Journal of Endocrinology</i> , 2018, 178, 173-180.	3.7	111
118	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV-“or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	2.8	97
119	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2018, 4, 1721.	7.1	1,625
120	Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation -“Authors’ reply. <i>Lancet Oncology</i> , The, 2018, 19, e367.	10.7	7
121	FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 2115-2120.	1.2	131
122	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018, 24, 5347-5356.	7.0	253
123	Immune checkpoint inhibitors in challenging populations. <i>Cancer</i> , 2017, 123, 1904-1911.	4.1	266
124	Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. <i>European Journal of Cancer</i> , 2017, 75, 169-178.	2.8	96
125	Immune Checkpoint Inhibitors for Brain Metastases. <i>Current Oncology Reports</i> , 2017, 19, 38.	4.0	18
126	A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. <i>Melanoma Research</i> , 2017, 27, 243-250.	1.2	12

#	ARTICLE	IF	CITATIONS
127	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5024-5033.	7.0	192
128	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. <i>British Journal of Cancer</i> , 2017, 116, 1558-1563.	6.4	91
129	Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. <i>Cancer</i> , 2017, 123, 2118-2129.	4.1	121
130	Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. <i>Annals of Oncology</i> , 2017, 28, 1130-1136.	1.2	253
131	Optimum dosing of ipilimumab in melanoma: too little, too late?. <i>Lancet Oncology</i> , The, 2017, 18, 558-559.	10.7	3
132	Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 759-766.	1.8	5
133	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 6054-6061.	7.0	75
134	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1202-1210.	10.7	211
135	Immune mediated neuropathy following checkpoint immunotherapy. <i>Journal of Clinical Neuroscience</i> , 2017, 45, 14-17.	1.5	49
136	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. <i>Modern Pathology</i> , 2017, 30, 1666-1676.	5.5	150
137	Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. <i>Biomarker Research</i> , 2017, 5, 17.	6.8	11
138	Advanced cancer patients' attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study. <i>European Journal of Cancer Care</i> , 2017, 26, e12600.	1.5	17
139	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. <i>Annals of Oncology</i> , 2017, 28, 368-376.	1.2	641
140	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 709-717.	1.6	829
141	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. <i>Biomarker Research</i> , 2017, 5, 32.	6.8	33
142	A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9508-9508.	1.6	98
143	Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9513-9513.	1.6	4
144	Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9541-9541.	1.6	2

#	ARTICLE	IF	CITATIONS
145	KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.. Journal of Clinical Oncology, 2017, 35, 9545-9545.	1.6	10
146	Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.. Journal of Clinical Oncology, 2017, 35, 51-51.	1.6	0
147	Residual ^{FDG}â€^{PET} metabolic activity in metastatic melanoma patients with prolonged response to antiâ€^{PD}â€1 therapy. Pigment Cell and Melanoma Research, 2016, 29, 572-577.	3.3	81
148	Optimizing combination dabrafenib and trametinib therapy in BRAF mutationâ€positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 5-12.	1.1	22
149	The molecular profile of metastatic melanoma in Australia. Pathology, 2016, 48, 188-193.	0.6	26
150	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature, 2016, 532, 250-254.	27.8	290
151	Biology and treatment of BRAF mutant metastatic melanoma. Melanoma Management, 2016, 3, 33-45.	0.5	28
152	Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. British Journal of Cancer, 2016, 115, 1280-1284.	6.4	36
153	Recent Developments in Melanoma Therapy. JAMA Oncology, 2016, 2, 1259.	7.1	5
154	Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology, 2016, 5, e1214788.	4.6	123
155	Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoringâ€The TADE Study. Clinical Cancer Research, 2016, 22, 3164-3171.	7.0	60
156	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2016, 2, 234.	7.1	534
157	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clinical Cancer Research, 2016, 22, 3915-3923.	7.0	91
158	Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology, 2016, 48, 261-266.	0.6	39
159	Prognostic utility of tumour infiltrating lymphocytes (TILs) and neutrophil-to-lymphocyte ratio (NLR) in early-stage triple negative breast cancer (TNBC).. Journal of Clinical Oncology, 2016, 34, 1075-1075.	1.6	1
160	Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.. Journal of Clinical Oncology, 2016, 34, 9506-9506.	1.6	30
161	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI).. Journal of Clinical Oncology, 2016, 34, 9515-9515.	1.6	10
162	Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma.. Journal of Clinical Oncology, 2016, 34, 9583-9583.	1.6	9

#	ARTICLE	IF	CITATIONS
163	An app to increase cross-referral and recruitment to melanoma clinical trials.. Journal of Clinical Oncology, 2016, 34, 9590-9590.	1.6	3
164	Clinical activity of the <sc>MEK</sc> inhibitor trametinib in metastatic melanoma containing <i><sc>BRAF</sc></i> kinase fusion. Pigment Cell and Melanoma Research, 2015, 28, 607-610.	3.3	70
165	Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with <sc>BRAF</sc> or combined <sc>BRAF</sc> and MEK inhibitors. Cancer, 2015, 121, 3826-3835.	4.1	40
166	Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. Journal of the American Academy of Dermatology, 2015, 72, 809-815.e1.	1.2	39
167	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer, 2015, 51, 2792-2799.	2.8	269
168	Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Annals of Oncology, 2015, 26, 415-421.	1.2	78
169	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Resistant Melanoma Patients. Clinical Cancer Research, 2015, 21, 3140-3148.	7.0	120
170	<sc>PD</sc>-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-<sc>PD</sc>-L1/<sc>PD</sc>-L1 clinical trials. Pigment Cell and Melanoma Research, 2015, 28, 245-253.	3.3	356
171	Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatology, 2015, 151, 1103.	4.1	139
172	Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor-Resistant Cutaneous Melanomas. Journal of Investigative Dermatology, 2015, 135, 532-541.	0.7	79
173	Patterns of acquired resistance to anti-PD-1 antibodies in patients with metastatic melanoma (MM).. Journal of Clinical Oncology, 2015, 33, e20005-e20005.	1.6	1
174	Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma. PLoS ONE, 2014, 9, e85004.	2.5	67
175	Reply to M. Perier-Muzet et al. Journal of Clinical Oncology, 2014, 32, 3203-3204.	1.6	3
176	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. Modern Pathology, 2014, 27, 1193-1202.	5.5	18
177	Intra-patient heterogeneity of BRAF mutation status: fact or fiction?. British Journal of Cancer, 2014, 111, 1678-1679.	6.4	9
178	Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 2014, 5, 5694.	12.8	295
179	Patterns of response and progression in patients with <i>BRAF</i>-mutant melanoma metastatic to the brain who were treated with dabrafenib. Cancer, 2014, 120, 530-536.	4.1	39
180	Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. American Journal of Surgical Pathology, 2014, 38, 377-382.	3.7	66

#	ARTICLE	IF	CITATIONS
181	Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. <i>Melanoma Research</i> , 2014, 24, 468-474.	1.2	42
182	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. <i>Clinical Cancer Research</i> , 2014, 20, 1965-1977.	7.0	447
183	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. <i>Cancer</i> , 2014, 120, 1695-1701.	4.1	195
184	Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment. <i>Journal of Immunology</i> , 2014, 192, 2505-2513.	0.8	69
185	Systemic treatment for BRAF-mutant melanoma: where do we go next?. <i>Lancet Oncology</i> , The, 2014, 15, e371-e381.	10.7	130
186	The nature and management of metastatic melanoma after progression on <scp>BRAF</scp> inhibitors: Effects of extended <scp>BRAF</scp> inhibition. <i>Cancer</i> , 2014, 120, 3142-3153.	4.1	65
187	Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 816-823.	1.6	20
188	Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2014, 111, 292-299.	6.4	93
189	Dabrafenib and Trametinib, Alone and in Combination for <i>BRAF</i>-Mutant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2014, 20, 2035-2043.	7.0	135
190	Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. <i>European Journal of Cancer</i> , 2013, 49, 3229-3241.	2.8	40
191	BRAF inhibitor activity in V600R metastatic melanoma – Response. <i>European Journal of Cancer</i> , 2013, 49, 1797-1798.	2.8	16
192	BRAF inhibitor activity in V600R metastatic melanoma. <i>European Journal of Cancer</i> , 2013, 49, 1073-1079.	2.8	105
193	18F-labelled fluorodeoxyglucose – positron emission tomography (FDG – PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. <i>European Journal of Cancer</i> , 2013, 49, 395-402.	2.8	42
194	BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. <i>British Journal of Cancer</i> , 2013, 108, 924-931.	6.4	55
195	Molecular biomarkers of prognosis in melanoma. <i>Melanoma Research</i> , 2013, 23, 423-425.	1.2	3
196	New combinations and immunotherapies for melanoma: latest evidence and clinical utility. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 278-285.	3.2	26
197	Paradoxical oncogenesis: are all <scp>BRAF</scp> inhibitors equal?. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 611-615.	3.3	44
198	Clinical characteristics and survival of BRAF-mutant (BRAF+) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9062-9062.	1.6	8

#	ARTICLE	IF	CITATIONS
199	Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation.. Journal of Clinical Oncology, 2013, 31, 543-543.	1.6	26
200	Clinicopathologic Features of V600E and V600K Melanomaâ€”Response. Clinical Cancer Research, 2012, 18, 6793-6793.	7.0	0
201	Distinguishing Clinicopathologic Features of Patients with V600E and V600K <i>BRAF</i> -Mutant Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 3242-3249.	7.0	405
202	Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy, 2012, 6, 391.	4.3	102
203	Correlates of fever in patients (pts) receiving combined dabrafenib (GSK2118436) plus trametinib (GSK1120212) for V600 BRAF-mutant metastatic melanoma (MM).. Journal of Clinical Oncology, 2012, 30, e19011-e19011.	1.6	3
204	<i>CYP2D6</i> genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.. Journal of Clinical Oncology, 2012, 30, 550-550.	1.6	0
205	Patterns of progression in patients (pts) with V600 BRAF-mutated melanoma metastatic to the brain treated with dabrafenib (GSK2118436).. Journal of Clinical Oncology, 2012, 30, 8558-8558.	1.6	3
206	Prognostic and Clinicopathologic Associations of Oncogenic <i>BRAF</i> in Metastatic Melanoma. Journal of Clinical Oncology, 2011, 29, 1239-1246.	1.6	942
207	Cutaneous sarcoidosis due to immuneâ€”checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor. Skin Health and Disease, 0, , e71.	1.5	2